Bibliographic Details
| Title: |
Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices |
| Authors: |
Shah, Palak, Looby, Mary, Dimond, Matthew, Bagchi, Pramita, Shah, Bhruga, Isseh, Iyad, Rollins, Allman T., Abdul-Aziz, Ahmad A., Kennedy, Jamie, Tang, Daniel G., Klein, Katherine M., Casselman, Samantha, Vermeulen, Christen, Sheaffer, Wendy, Snipes, Meredith, Sinha, Shashank S., O’Connor, Christopher M. |
| Source: |
JACC: Heart Failure; September 2024, Vol. 12 Issue: 9 p1540-1549, 10p |
| Abstract: |
Patients receiving left ventricular assist device (LVAD) support require long-term anticoagulation to reduce the risk of thromboembolic complications. Apixaban is a direct oral anticoagulant that has become first-line therapy; however, its safety in LVAD recipients has not been well described. |
| Database: |
Supplemental Index |
